GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » FCF Margin %

MYND Life Sciences (XCNQ:MYND) FCF Margin % : 0.00% (As of Jul. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MYND Life Sciences's Free Cash Flow for the three months ended in Jul. 2024 was C$-0.00 Mil. MYND Life Sciences's Revenue for the three months ended in Jul. 2024 was C$0.00 Mil. Therefore, MYND Life Sciences's FCF Margin % for the quarter that ended in Jul. 2024 was 0.00%.

As of today, MYND Life Sciences's current FCF Yield % is -11.97%.

The historical rank and industry rank for MYND Life Sciences's FCF Margin % or its related term are showing as below:


XCNQ:MYND's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -142.95
* Ranked among companies with meaningful FCF Margin % only.


MYND Life Sciences FCF Margin % Historical Data

The historical data trend for MYND Life Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences FCF Margin % Chart

MYND Life Sciences Annual Data
Trend Oct21 Oct22 Oct23
FCF Margin %
- - -

MYND Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MYND Life Sciences's FCF Margin %

For the Biotechnology subindustry, MYND Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MYND Life Sciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MYND Life Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where MYND Life Sciences's FCF Margin % falls into.


;
;

MYND Life Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

MYND Life Sciences's FCF Margin for the fiscal year that ended in Oct. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Oct. 2023 )/Revenue (A: Oct. 2023 )
=-0.198/0
= %

MYND Life Sciences's FCF Margin for the quarter that ended in Jul. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Jul. 2024 )/Revenue (Q: Jul. 2024 )
=-0.001/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MYND Life Sciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


MYND Life Sciences Business Description

Traded in Other Exchanges
Address
105-2248 Elgin Avenue, Port Coquitlam, BC, CAN, V3C 2B2
MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.